Haemopoiesis Clinical application
... (These factors have the capacity to stimulate the proliferation of their target progenitor cells when used as a sole source of stimulation) ...
... (These factors have the capacity to stimulate the proliferation of their target progenitor cells when used as a sole source of stimulation) ...
Angiology 脉管系统
... Schwann cells Form myelin sheaths around the larger nerve fibers in the PNS. Vital to neuronal regeneration ...
... Schwann cells Form myelin sheaths around the larger nerve fibers in the PNS. Vital to neuronal regeneration ...
Lecture 2 - IMaGeS Lab
... variety of cell types in response to bacterial products, viruses, and agents that cause physical damage. ...
... variety of cell types in response to bacterial products, viruses, and agents that cause physical damage. ...
021809.M1-Immuno.DiabetesAndReview
... become cytotoxic. Alternatively, the CD4+ T cells may produce large amounts of interferon-, and activate macrophages. Both cytotoxic CD8+ T cells and activated macrophages eliminate the intracellular pathogen by killing the cell in which it resides. Many intracellular bacteria grow only in macropha ...
... become cytotoxic. Alternatively, the CD4+ T cells may produce large amounts of interferon-, and activate macrophages. Both cytotoxic CD8+ T cells and activated macrophages eliminate the intracellular pathogen by killing the cell in which it resides. Many intracellular bacteria grow only in macropha ...
The Immune System Terminology Glossary
... acids are the building blocks of a cell, and a gene determines how each molecule is produced. monoclonal antibodies—antibodies produced by a single cell or its identical progeny, specific for a given antigen. As tools for binding to specific protein molecules, they are invaluable in research, medici ...
... acids are the building blocks of a cell, and a gene determines how each molecule is produced. monoclonal antibodies—antibodies produced by a single cell or its identical progeny, specific for a given antigen. As tools for binding to specific protein molecules, they are invaluable in research, medici ...
To view Press Release as PDF
... promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing apoptosis, s ...
... promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in multiple cancer types in addition to ovarian cancer, including breast, colon and lung cancers. Survivin plays an essential role in antagonizing apoptosis, s ...
Logic of the Immune System - Cancer Immunology Research
... kill cancerous cells or pathogen-infected cells to which the immunoglobulin latched on via its variable region. The ability to access the different constant regions is a differentiation event carefully controlled in the life of a B lymphocyte. For a newly generated B cell, the constant region used i ...
... kill cancerous cells or pathogen-infected cells to which the immunoglobulin latched on via its variable region. The ability to access the different constant regions is a differentiation event carefully controlled in the life of a B lymphocyte. For a newly generated B cell, the constant region used i ...
Anti-Viral Immunity in Coronary Heart Disease
... differentiated CD8+ effector memory cells in peripheral blood compared to CMV- patients, and this fall persisted for 3 months. The cells that reduced in number were specific for CMV, secreted the pro-inflammatory cytokine gamma interferon, and possessed the programmed cell death (PD-1) marker. Cells ...
... differentiated CD8+ effector memory cells in peripheral blood compared to CMV- patients, and this fall persisted for 3 months. The cells that reduced in number were specific for CMV, secreted the pro-inflammatory cytokine gamma interferon, and possessed the programmed cell death (PD-1) marker. Cells ...
tools in develoomental biology
... Sea urchin (echinoderm) Many systems available: which one to use: most powerful one where you can study your questions of interest. (also, many of these model systems are used to study processes other than developmental biology). ...
... Sea urchin (echinoderm) Many systems available: which one to use: most powerful one where you can study your questions of interest. (also, many of these model systems are used to study processes other than developmental biology). ...
White 1: Blood Information
... Have specific antigen receptors that will bind to cells infected by certain antigens. Once they bind they will send a chemical signal to other cells to come help destroy the cell. ...
... Have specific antigen receptors that will bind to cells infected by certain antigens. Once they bind they will send a chemical signal to other cells to come help destroy the cell. ...
The Body`s Defenses Against Disease and Injury
... The body recognizes if a substance is self- or nonself-made as a result of certain antigens that are present on almost all cells of the body except red blood cells. This determines compatibility of tissues and organs that will be grafted or transplanted from a donor. Blood Group Antigens More than 8 ...
... The body recognizes if a substance is self- or nonself-made as a result of certain antigens that are present on almost all cells of the body except red blood cells. This determines compatibility of tissues and organs that will be grafted or transplanted from a donor. Blood Group Antigens More than 8 ...
In vivo protein biotinylation for identification of organ
... Recently, acetyl CoA carboxylase 265 has been identified as a partner of the protein encoded by the breast cancer susceptibility gene BRCA1. This report show that acetyl CoA carboxylase 256 is either more abundant, more easily accessible, or both in the tumors tested than in other normal tissues, su ...
... Recently, acetyl CoA carboxylase 265 has been identified as a partner of the protein encoded by the breast cancer susceptibility gene BRCA1. This report show that acetyl CoA carboxylase 256 is either more abundant, more easily accessible, or both in the tumors tested than in other normal tissues, su ...
Slide 1
... receptors; corticoids inhibit histamine synthesis; effects on membrane composition – inhibition of degranulation) ...
... receptors; corticoids inhibit histamine synthesis; effects on membrane composition – inhibition of degranulation) ...
slides#5 - DENTISTRY 2012
... Overview of the stages of lymphocyte development and function Antigen Indpendeny Development ...
... Overview of the stages of lymphocyte development and function Antigen Indpendeny Development ...
Immunotherapy: Targeting Cancer with the Immune System
... http://www.cancer.gov/aboutcancer/treatment/drugs/recombinant-interferon-alfa2b), promote the activation and activity of natural killer cells (with direct tumor-killing ability) and dendritic cells (which can promote additional patient-derived immunity to cancer). These agents have been in widesprea ...
... http://www.cancer.gov/aboutcancer/treatment/drugs/recombinant-interferon-alfa2b), promote the activation and activity of natural killer cells (with direct tumor-killing ability) and dendritic cells (which can promote additional patient-derived immunity to cancer). These agents have been in widesprea ...
Document
... while impeding microbial growth -However, very high fevers are hazardous as they may denature critical enzymes ...
... while impeding microbial growth -However, very high fevers are hazardous as they may denature critical enzymes ...
39_Autoimmune diseases_LA
... Prednisone unresponsive patients: splenectomy may be considered. (Pneumococcus vaccine before treatment) Immunotherapy, antibodies IVIG Anti-CD20 (rituximab) Plasmapheresis ...
... Prednisone unresponsive patients: splenectomy may be considered. (Pneumococcus vaccine before treatment) Immunotherapy, antibodies IVIG Anti-CD20 (rituximab) Plasmapheresis ...
Chapter 3
... clonal selection also provides an explanation for memory in the immune system. Clonal selection makes a lot of sense, has been confirmed to be correct in countless experiments, and is the first law of cellular immunology. The antibody plaque assay The clonal selection theory is now generally accepte ...
... clonal selection also provides an explanation for memory in the immune system. Clonal selection makes a lot of sense, has been confirmed to be correct in countless experiments, and is the first law of cellular immunology. The antibody plaque assay The clonal selection theory is now generally accepte ...
Evolution of Immune Systems
... • Porifera have polymorphic ‘MHC genes” with multiple loci • MHC have no structural similarities to vertebrate MHC - proteoglycan complex ...
... • Porifera have polymorphic ‘MHC genes” with multiple loci • MHC have no structural similarities to vertebrate MHC - proteoglycan complex ...
BIO CEO Presentation - Trillium Therapeutics Inc.
... Trillium Therapeutics Inc. (NASDAQ:TRIL/TSX:TR) is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. ...
... Trillium Therapeutics Inc. (NASDAQ:TRIL/TSX:TR) is an immuno-oncology company dedicated to the discovery and development of novel and innovative cancer therapies. ...
The Immune System- Dr Masoud Sirati Nir
... A. protein that NK cells use to kill invading cells 2. ______ tonsil B. substance that induces sensitivity or an immune response 3. ______ lymph node C. cells that make up about 80% of lymphocytes, the “T” denoting their work with the thymus 4. ______ perforin D. immune system gland, located behind ...
... A. protein that NK cells use to kill invading cells 2. ______ tonsil B. substance that induces sensitivity or an immune response 3. ______ lymph node C. cells that make up about 80% of lymphocytes, the “T” denoting their work with the thymus 4. ______ perforin D. immune system gland, located behind ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.